Comparative Clinical-Imaging and Histogenetic Analysis Between Astrocytoma IDH-Mutant Grade 4 and Glioblastoma IDH-Wildtype—Is There Really a Worse One?

Diagnostics, Journal Year: 2025, Volume and Issue: 15(4), P. 438 - 438

Published: Feb. 11, 2025

Background: Brain tumors pose a significant health threat, leading to high morbidity and mortality rates. Astrocytoma IDH-mutant grade 4 (A4IDHmt) glioblastoma IDH-wildtype (G4IDHwt) exhibit similar clinical imaging characteristics. This study aims highlight the differences in their evolution histogenetic aspects with possible therapeutic impact, as well adverse prognostic factors patient survival. Methods: We performed 10-year retrospective of gliomas, evaluating immunomarkers FISH tests. also quantified tumor necrosis microvascular density. Results: A total 81 cases were identified; 54.32% A4IDHmt. observed that A4IDHmt patients younger (34.10% under 50) had higher survival rate (4.55%). group exhibited more pronounced density (p = 0.010) proliferative index 0.026). G4IDHwt was associated larger volumes (94.84 cm3 vs. 86.14 cm3), lower resectability rates (82.88% 87.67%), immature cell population (83.78% 68.18%). In case both, negative risk on univariate analysis is given by advanced age (A4IDHmt: HR 1.035, G4IDHwt: 1.045) p53 immunopositivity 6.962, 4.680). Conclusions: The for include rapid onset symptoms (HR 2.038), diabetes mellitus 2.311), arterial hypertension 2.325), residual 2.662), increased volume 1.060), 1.096), 1.097). For G4IDHwt, consist 1.023), lost PTEN immunoreaction 33.133), unmethylated DNA status 6.765, respectively 20.573). Even if it has factors, lesser evil.

Language: Английский

---

Unraveling the Complexities of Myeloid-Derived Suppressor Cells in Inflammatory Bowel Disease

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 3291 - 3291

Published: April 2, 2025

Myeloid-derived suppressor cells (MDSCs) regulate immune responses in many pathological conditions, one of which is inflammatory bowel disease (IBD), an incurable chronic disorder the digestive tract and beyond. The pathophysiology IBD remains unclear, likely involving aberrant innate adaptive immunity. Studies have reported altered population MDSCs patients with IBD. However, their distribution varies among different preclinical models expansion activation are driven by various stimuli during intestinal inflammation, but in-depth mechanisms remain poorly understood. role pathogenesis appears to be paradoxical. In addition suppressive may promote colitis-to-colon cancer transition. this Review, we summarize recent progresses on features, activation, roles development IBD-associated colon cancer.

Language: Английский

---

Combined anti-PD-L1 and anti-VEGFR2 therapy promotes the antitumor immune response in GBM by reprogramming tumor microenvironment

Cell Death Discovery, Journal Year: 2025, Volume and Issue: 11(1)

Published: April 3, 2025

Abstract Inhibitors of programmed cell death ligand 1 (PD-L1) and vascular endothelial growth factor receptor 2 (VEGFR2) are commonly used in the clinic, but they beneficial for only a minority glioblastoma multiforme (GBM) patients. GBM has significant immunosuppressive properties, there many cells dysfunctional effector T tumor microenvironment (TME), which is one important reasons failure clinical treatment GBM. Here, we have identified P21 activated kinase 4 (PAK4) as pivotal immune suppressor TME. PAK4 threonine protein kinase, knockdown attenuates abnormalities promotes T-cell infiltration. In this study, our results showed that expression was significantly downregulated after VEGFR2 knockdown. Next, constructed coculture system CD8+ cells. Our findings combined anti-PD-L1 anti-VEGFR2 therapy can regulate TME inhibit cells' escape; overexpression reverse effect. Finally, tested combination mouse intracranial graft models found prolong survival. These suggest downregulate PAK4, reprogram by increasing cytotoxic infiltration activation, enhance therapeutic effect on

Language: Английский

---

OncoSexome: the landscape of sex-based differences in oncologic diseases

Nucleic Acids Research, Journal Year: 2024, Volume and Issue: 53(D1), P. D1443 - D1459

Published: Nov. 13, 2024

The NIH policy on sex as biological variable (SABV) emphasized the importance of sex-based differences in precision oncology. Over 50% clinically actionable oncology genes are sex-biased, indicating drug efficacy. Research has identified non-reproductive cancers, highlighting need for comprehensive cancer data. We therefore developed OncoSexome, a multidimensional knowledge base describing (https://idrblab.org/OncoSexome/) across four key topics: antineoplastic drugs and responses (SDR), oncology-related biomarkers (SBM), risk factors (SRF) microbial landscape (SML). SDR covers 2051 anticancer drugs; SBM describes 12 551 sex-differential biomarkers; SRF illustrates 350 sex-dependent factors; SML demonstrates 1386 microbes with abundances associated development. OncoSexome is unique illuminating multifaceted influences cancer, providing both external endogenous contributors to development broadest oncological classes. Given increasing global research interest differences, expected impact future practices significantly.

Language: Английский

---

Sex differences in the molecular profile of adult diffuse glioma are shaped by IDH status and tumor microenvironment

Neuro-Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 5, 2024

Abstract Background Sex differences in adult diffuse glioma (ADG) are well established clinically, yet the underlying molecular mechanisms remain inadequately understood. Here, we aim to reveal features and cellular compositions unique each sex ADG comprehend role of disease etiology. Methods We quantified transcriptome using multiple independent patient datasets. Next, delved into single-cell landscape examine gene expression composition. To explore how influences progression, analyzed paired samples from primary recurrent cases, aiming identify sex-specific features. Results Our analysis revealed that mutations isocitrate dehydrogenase (IDH) genes tumor microenvironment emerged as influencers sex-differential enrichments. In IDHwt tumors, neuronal signaling pathway found be enriched male while hypoxia inflammatory response pathways female tumors. This pattern was reversed IDHmut gliomas. hypothesized these distinctions could attributed heterogeneous composition between sexes. Using data, observed distinctive patterns cell states, composition, cell–cell interaction tumors separately. Further, by comparing changes samples, identified characteristics Conclusions results provide a comprehensive multilevel characterization ADG; such findings novel insights progression sex.

Language: Английский

---

A triad between sex, necrosis, and inflammation shapes glioblastoma outcomes

Neuro-Oncology, Journal Year: 2024, Volume and Issue: 26(7), P. 1228 - 1229

Published: May 14, 2024

Journal Article Accepted manuscript A triad between sex, necrosis, and inflammation shapes glioblastoma outcomes Get access Brandon Emanuel León, León Department of Molecular Cellular Pharmacology, Miller School Medicine, University Miami, FLSylvester Comprehensive Cancer Center, FL Search for other works by this author on: Oxford Academic PubMed Google Scholar Defne Bayik Corresponding author: [email protected] https://orcid.org/0000-0002-4740-8869 Neuro-Oncology, noae086, https://doi.org/10.1093/neuonc/noae086 Published: 14 May 2024 history Received: 23 April

Language: Английский

---

Sex differences in glioblastoma based on tumor subtypes

Neuro-Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: May 9, 2024

Journal Article Corrected proof Sex differences in glioblastoma based on tumor subtypes Get access Berta Segura-Collar, Segura-Collar Instituto de investigaciones Biomédicas I+12 (Imas12), Hospital 12 Octubre, Madrid, SpainPathology and Neurooncology Unit, Universitario Spain Corresponding Author: PhD, Pathology Av. Córdoba, S/N, 28041 ([email protected]) https://orcid.org/0000-0001-8507-7434 Search for other works by this author on: Oxford Academic PubMed Google Scholar Ricardo Gargini SpainInstituto Gargini, ([email protected]) https://orcid.org/0000-0003-4032-0095 Neuro-Oncology, noae089, https://doi.org/10.1093/neuonc/noae089 Published: 17 June 2024 history typeset:

Language: Английский

---

The Sybil prophecy: Searching for predictors of response to bevacizumab in glioblastoma

Neuro-Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: June 17, 2024

Journal Article Corrected proof The Sybil prophecy: Searching for predictors of response to bevacizumab in glioblastoma Get access Martina Offi, Offi Department Neuroscience, Catholic University School Medicine, ItalyDepartment Neurosurgery, Fondazione Policlinico Gemelli IRCCS, Italy Search other works by this author on: Oxford Academic PubMed Google Scholar Lucia Gabriele, Gabriele Oncology and Molecular Istituto Superiore di Sanità, Rome, Giulia Romagnoli, Romagnoli Liverana Lauretti, Lauretti https://orcid.org/0000-0001-7997-1624 Roberto Pallini, Pallini Corresponding Author: MD, PhD, Largo A. Gemelli, 8, 00168 ([email protected]). https://orcid.org/0000-0002-4611-8827 Quintino Giorgio D'Alessandris Neuro-Oncology, noae088, https://doi.org/10.1093/neuonc/noae088 Published: 17 June 2024 history typeset:

Language: Английский

---

Gene expression signature-defined necroinflammation is not associated with sex-biased survival or bevacizumab benefit in glioblastoma

Neuro-Oncology, Journal Year: 2024, Volume and Issue: 27(1), P. 306 - 308

Published: Oct. 10, 2024

Journal Article Corrected proof Gene expression signature-defined necroinflammation is not associated with sex-biased survival or bevacizumab benefit in glioblastoma Get access Johannes Weller, Weller Department of Vascular Neurology, Center University Hospital Bonn, GermanyCenter Integrated Oncology (CIO ABCD), GermanyDepartment Neurooncology, Germany Corresponding Author: MD, Venusberg Campus 1, 53121 ([email protected]). https://orcid.org/0000-0001-5818-5392 Search for other works by this author on: Oxford Academic PubMed Google Scholar Emre Kocakavuk, Kocakavuk Hematology and Stem Cell Transplantation, West German Cancer Center, Essen, Barbara Pregler, Pregler Neurosurgery, Thomas Zeyen, Zeyen https://orcid.org/0009-0006-2919-8622 Niklas Schäfer, Schäfer Anna-Laura Potthoff, Potthoff https://orcid.org/0000-0002-5710-6557 Matthias Schneider, Schneider https://orcid.org/0000-0002-6025-7479 Ulrich Herrlinger Neuro-Oncology, noae216, https://doi.org/10.1093/neuonc/noae216 Published: 15 November 2024 history typeset:

Language: Английский

---

Sex differences show responders to bevacizumab

Neuro-Oncology, Journal Year: 2024, Volume and Issue: 27(1), P. 309 - 310

Published: Oct. 14, 2024

Journal Article Corrected proof Sex differences show responders to bevacizumab Get access Berta Segura-Collar, Segura-Collar Instituto de investigaciones Biomédicas I+12 (Imas12), Hospital 12 Octubre, Madrid 28041, SpainPathology and Neurooncology Unit, Universitario Spain Corresponding Author: PhD, Pathology Av. Córdoba, S/N, 28041 Madrid, ([email protected]). https://orcid.org/0000-0001-8507-7434 Search for other works by this author on: Oxford Academic PubMed Google Scholar Sara Hiller-Vallina, Hiller-Vallina Ricardo Gargini Gargini, ([email protected]) https://orcid.org/0000-0003-4032-0095 Neuro-Oncology, noae217, https://doi.org/10.1093/neuonc/noae217 Published: 15 November 2024 history typeset:

Language: Английский

---